Weber Capital Management LLC ADV Invests $2.35 Million in Treace Medical Concepts, Inc. $TMCI

Weber Capital Management LLC ADV bought a new stake in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 589,617 shares of the company’s stock, valued at approximately $2,346,676. Treace Medical Concepts makes up about 0.0% of Weber Capital Management LLC ADV’s investment portfolio, making the stock its 10th biggest position. Weber Capital Management LLC ADV owned approximately 0.91% of Treace Medical Concepts as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in TMCI. Graham Capital Management L.P. purchased a new position in Treace Medical Concepts in the fourth quarter worth $27,000. Osaic Holdings Inc. raised its position in Treace Medical Concepts by 328.3% during the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock valued at $28,000 after acquiring an additional 3,674 shares in the last quarter. HighTower Advisors LLC bought a new position in Treace Medical Concepts during the fourth quarter valued at about $33,000. Chicago Partners Investment Group LLC raised its stake in shares of Treace Medical Concepts by 34.0% in the first quarter. Chicago Partners Investment Group LLC now owns 26,014 shares of the company’s stock worth $35,000 after acquiring an additional 6,606 shares during the last quarter. Finally, Hsbc Holdings PLC raised its holdings in Treace Medical Concepts by 26.8% during the 1st quarter. Hsbc Holdings PLC now owns 30,994 shares of the company’s stock worth $40,000 after buying an additional 6,554 shares during the period. 84.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TMCI. Wall Street Zen upgraded Treace Medical Concepts from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings lowered Treace Medical Concepts from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. Finally, Truist Financial raised their price objective on Treace Medical Concepts from $4.00 to $5.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Treace Medical Concepts presently has an average rating of “Reduce” and a consensus target price of $5.17.

Insider Buying and Selling at Treace Medical Concepts

In other news, CEO John T. Treace acquired 50,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was acquired at an average price of $3.56 per share, with a total value of $178,000.00. Following the completion of the purchase, the chief executive officer directly owned 7,323,833 shares in the company, valued at approximately $26,072,845.48. This trade represents a 0.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 158,261 shares of company stock worth $635,613 in the last three months. 23.42% of the stock is currently owned by corporate insiders.

Treace Medical Concepts Stock Performance

TMCI stock traded up $0.05 during mid-day trading on Friday, reaching $4.65. 149,779 shares of the stock traded hands, compared to its average volume of 730,773. The business has a 50-day moving average of $4.40 and a two-hundred day moving average of $2.96. Treace Medical Concepts, Inc. has a 52 week low of $1.17 and a 52 week high of $7.63. The firm has a market capitalization of $302.44 million, a PE ratio of -5.00 and a beta of 1.37. The company has a quick ratio of 1.95, a current ratio of 2.90 and a debt-to-equity ratio of 0.83.

Treace Medical Concepts (NASDAQ:TMCI) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.06. The firm had revenue of $45.38 million for the quarter, compared to analyst estimates of $44.02 million. Treace Medical Concepts had a negative return on equity of 71.37% and a negative net margin of 28.99%. As a group, equities analysts predict that Treace Medical Concepts, Inc. will post -0.83 EPS for the current fiscal year.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.